Shots: The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to […]readmore
Tags : Lebrikizumab
Shots: Lilly acquires Dermira in all-cash transaction making total deal value ~$1.1B at $18.75/share representing premium of 86% to the 60-day volume-weighted average trading price of Dermira’s stock ending on […]readmore
Shots: Dermira to receive $50M as an option exercise fee, $30M milestone with the initiation of P-III studies, $85M as the regulatory & commercial milestone and royalties on sales. Almirall […]readmore
Shots: Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU, with […]readmore